DocuSign Envelope ID: F7EB27A7-E00F-4551-8B67-2EBA3DB04B90

September 13, 2021

Dear Members and Friends of the Association for Creatine Deficiencies (ACD),

First and foremost, we hope this update finds you and your families continuing to stay safe and healthy. Enclosed is an important update about the Vigilan study on behalf of the Ultragenyx Vigilan study team.

In May of this year, we provided a comprehensive update about Vigilan, an observational study focused on understanding the natural history of CTD over a period of 48 months (or four years). The letter discussed the number of enrolled patients, location of active study sites, impact of COVID-19 on the study, and the ongoing analysis of Vigilan data in preparation for development of the study's first manuscript. You can access that complete update here.

Ultragenyx is proud to announce that we have successfully met the enrollment target of 50 patients! Some patients have already completed their 48 months of protocol assessments and the remaining patients will also have the opportunity to complete their 48 months of protocol assessments. This enables us to continue gathering valuable information about the clinical signs and symptoms of CTD, including effects on behavior and intellectual and physical development. We are extremely grateful to the patients living with CTD and their families for their participation and all that they have done and continue to do to help advance research. As you know, Vigilan represents the first longitudinal natural history study in the CTD population, and this landmark research would not be possible without you.

In addition, we have recently completed a snapshot and review of the current data for Vigilan, with a particular focus on the first two years of participation for each patient. Ultragenyx worked very closely with Vigilan's Joint Steering Committee (JSC), the governing body responsible for the study's strategy and publication plan, and each site's staff to successfully complete this data snapshot. We are very appreciative of the JSC and each study site for their collective commitment to meeting this important milestone. The wealth of information from this review should make for a very informative manuscript and will help to inform Ultragenyx's clinical development program (UX068), and also provide information for others working in this area.

Looking ahead, data from the remaining patient visits will provide necessary information to establish the applicability of the new assessments included in Protocol Amendment 6, which were added to capture some additional aspects of CTD based on learnings from an initial data assessment previously conducted. The remaining patients in Vigilan will play a critical role in advancing CTD research because data on these new assessments will help guide our strategy for potential future clinical trials.

With enrollment complete and the data snapshot finished, the study team will now focus on completion of the 48 months of assessments for the remaining patients in the study. We currently anticipate that the study will be completed during the summer of 2024, which is when the final patient visit is expected. If you are enrolled in Vigilan and have questions about the study and your participation, please contact your site directly.

DocuSign Envelope ID: F7EB27A7-E00F-4551-8B67-2EBA3DB04B90

The Ultragenyx CTD team remains steadfast in our commitment to advancing CTD research. We will work closely with the JSC and other CTD experts to identify unique opportunities that may enable continued learning about the natural history of CTD outside of Vigilan's ongoing research and we look forward to sharing updates with you as new information becomes available. In the meantime, you can access and download rare disease education and tools on our Patient Advocacy website at UltraRareAdvocacy.com and follow us on Facebook at Facebook.com/Ultragenyx.

Sincerely,

DocuSigned by:
Jessica Riviere
2985924F8444445...

Jessica Riviere
Vice President of Patient Advocacy and Patient Engagement